SGR-1505

SGR-1505 is an orally active MALT1 allosteric inhibitor. SGR-1505 inhibits MALT1 enzymatic activity and shows anti-proliferative activity in BTK inhibitor (BTKi) -sensitive and BTKi-resistant activated B cell-like diffuse large B cell lymphoma (ABC-DLBCL) cell lines. SGR-1505 can be used for research of B-cell lymphomas[1].

Product Specifications

CAS Number

[2661481-41-8]

UNSPSC

12352005

Target

MALT1

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease; NF-κB

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/sgr-1505.html

Concentration

10mM

Purity

99.89

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

FC(F)([C@]1(C2=C(C=NC3=CC(F)=NN32)N(C1)C(NC4=CN=C(N5N=CC=N5)C(Cl)=C4)=O)C)F

Molecular Formula

C18H12ClF4N9O

Molecular Weight

481.79

References & Citations

[1]Adam Olszewski MD, et al. A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of Sgr-1505 As Monotherapy in Subjects with Mature B-Cell Malignancies.Blood. Volume 142, Supplement 1, 2 November 2023, Page 3102.